James Peyer, Director, 10% Owner at Sensei Biotherapeutics, Inc. (SNSE), bought 30,000 shares at $4.40 ($133K) on 2022-02-11, disclosed to the SEC on 2022-02-14.
Open-market purchase of $133k SNSE by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.58 | 5,000 | $23K | 17.2% |
| 2 | $4.40 | 12,500 | $55K | 41.4% |
| 3 | $4.40 | 12,500 | $55K | 41.4% |
| Total | $4.43 avg | 30,000 | $133K | 100% |
| Filing → |
| SNSE | SELL | 2025-12-08 | $398K | — | Filing → |
| SNSE | BUY | 2022-04-21 | $15K | — | Filing → |
| SNSE | BUY | 2022-04-21 | $136K | — | Filing → |